Advancements in Genetic and Biochemical Insights: Unraveling the Etiopathogenesis of Neurodegeneration in Parkinson’s Disease
暂无分享,去创建一个
A. Pareek | Y. Ratan | A. Rajput | Aaushi Pareek | Gurjit Singh | Zeba Farooqui | Vivek Jain | Sonia Sonia | Ranjeet Kaur
[1] Lanxia Meng,et al. The yeast prion protein Sup35 initiates α-synuclein pathology in mouse models of Parkinson’s disease , 2023, Science Advances.
[2] Jongkyun Kang,et al. Cell autonomous role of leucine-rich repeat kinase in protection of dopaminergic neuron survival , 2023, bioRxiv.
[3] Ninghui Zhao,et al. Iron‐inhibited autophagy via transcription factor ZFP27 in Parkinson's disease , 2023, Journal of cellular and molecular medicine.
[4] Kyu-Sang Park,et al. PINK1 and Parkin regulate IP3R-mediated ER calcium release , 2023, Nature communications.
[5] H. Motaln,et al. The Role of c-Abl Tyrosine Kinase in Brain and Its Pathologies , 2023, Cells.
[6] S. Mastana,et al. Targeting calcium homeostasis and impaired inter-organelle crosstalk as a potential therapeutic approach in Parkinson's disease. , 2023, Life sciences.
[7] N. Hattori,et al. Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson’s disease , 2023, NPJ Parkinson's disease.
[8] J. Prasuhn,et al. Neuroinflammation and Mitochondrial Dysfunction in Parkinson’s Disease: Connecting Neuroimaging with Pathophysiology , 2023, Antioxidants.
[9] Liyan Hou,et al. Serum metabolomics analysis revealed metabolic disorders in Parkinson’s disease , 2023, Medicine.
[10] A. Kakita,et al. Phosphorylation of α-synuclein at T64 results in distinct oligomers and exerts toxicity in models of Parkinson’s disease , 2023, Proceedings of the National Academy of Sciences of the United States of America.
[11] Qi Zhou,et al. The role of the microbiota-gut-brain axis and intestinal microbiome dysregulation in Parkinson’s disease , 2023, Frontiers in Neurology.
[12] Mohamed Salama,et al. The Role of an Altered Gut Microbiome in Parkinson’s Disease: A Narrative Review , 2023, Applied Microbiology.
[13] V. Jain,et al. An Insight into Cellular and Molecular Mechanisms Underlying the Pathogenesis of Neurodegeneration in Alzheimer’s Disease , 2023, Biomedicines.
[14] J. Pu,et al. Nuclear DJ-1 Regulates DNA Damage Repair via the Regulation of PARP1 Activity , 2023, International journal of molecular sciences.
[15] Jing Zhang,et al. The cervical lymph node contributes to peripheral inflammation related to Parkinson’s disease , 2023, Journal of Neuroinflammation.
[16] Jia Meng,et al. SIRT1/FOXO3-mediated autophagy signaling involved in manganese-induced neuroinflammation in microglia. , 2023, Ecotoxicology and environmental safety.
[17] Jie Zhou,et al. Upregulation of mitochondrial calcium uniporter contributes to paraquat-induced neuropathology linked to Parkinson's disease via imbalanced OPA1 processing. , 2023, Journal of hazardous materials.
[18] A. Kortholt,et al. LRRK2 Structure-Based Activation Mechanism and Pathogenesis , 2023, Biomolecules.
[19] Sevim Isik,et al. Microglia Mediated Neuroinflammation in Parkinson’s Disease , 2023, Cells.
[20] S. Khoshnam,et al. Mitochondrial Dysfunction and Parkinson’s Disease: Pathogenesis and Therapeutic Strategies , 2023, Neurochemical Research.
[21] M. Grothe,et al. Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease , 2023, Movement disorders : official journal of the Movement Disorder Society.
[22] P. Calabresi,et al. Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction , 2023, Cell Death & Disease.
[23] A. Bortolozzi,et al. The Role of α-Synuclein in the Regulation of Serotonin System: Physiological and Pathological Features , 2023, Biomedicines.
[24] Li Gu,et al. α-Synuclein Induced the Occurrence of RBD via Interaction with OX1R and Modulated Its Degradation , 2023, NeuroMolecular Medicine.
[25] I. Majsterek,et al. GBA1 Gene Mutations in α-Synucleinopathies—Molecular Mechanisms Underlying Pathology and Their Clinical Significance , 2023, International journal of molecular sciences.
[26] M. Feany,et al. α-Synuclein Promotes Neuronal Dysfunction and Death by Disrupting the Binding of Ankyrin to β-Spectrin , 2023, Journal of Neuroscience.
[27] D. Keszthelyi. Targeting the enteric nervous system to treat constipation in Parkinson's disease. , 2023, Gastroenterology.
[28] A. Koppes,et al. Aggregation of alpha-synuclein in enteric neurons does not impact function in vitro , 2022, Scientific reports.
[29] S. Dahbour,et al. Non-motor manifestation of Parkinson's disease: a cross-sectional study in a teaching hospital in Jordan , 2022, The Egyptian Journal of Neurology, Psychiatry and Neurosurgery.
[30] Yan Liang,et al. Interactions between gut microbiota and Parkinson's disease: The role of microbiota-derived amino acid metabolism , 2022, Frontiers in Aging Neuroscience.
[31] Y. Sung,et al. HtrA2 regulates α-Synuclein-mediated mitochondrial reactive oxygen species production in the mitochondria of microglia. , 2022, Biochemical and biophysical research communications.
[32] Chen Liang,et al. Vagus Nerve and Underlying Impact on the Gut Microbiota-Brain Axis in Behavior and Neurodegenerative Diseases , 2022, Journal of inflammation research.
[33] Farhan Mohammad,et al. Gut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment , 2022, Journal of advanced research.
[34] W. Kim,et al. LRRK2 and Lipid Pathways: Implications for Parkinson’s Disease , 2022, Biomolecules.
[35] Z. Yue,et al. Gut bacterial profiles in Parkinson's disease: A systematic review , 2022, CNS neuroscience & therapeutics.
[36] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[37] Scott D. Ryan,et al. Nitrosative stress in Parkinson’s disease , 2022, npj Parkinson's Disease.
[38] G. Logroscino,et al. Descriptive Epidemiology of Neurodegenerative Diseases: What Are the Critical Questions? , 2022, Neuroepidemiology.
[39] Xiaoying Gao,et al. Mitochondrial Dysfunction in Parkinson’s Disease: From Mechanistic Insights to Therapy , 2022, Frontiers in Aging Neuroscience.
[40] R. Krüger,et al. Neurodegeneration and Neuroinflammation in Parkinson’s Disease: a Self-Sustained Loop , 2022, Current Neurology and Neuroscience Reports.
[41] P. Verstreken,et al. Parkinsonism mutations in DNAJC6 cause lipid defects and neurodegeneration that are rescued by Synj1 , 2022, bioRxiv.
[42] U. Sengupta,et al. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases , 2022, Progress in Neurobiology.
[43] K. Del Tredici,et al. Gastrointestinal involvement in Parkinson’s disease: pathophysiology, diagnosis, and management , 2022, NPJ Parkinson's disease.
[44] M. Farrer,et al. The Gut–Brain Axis and Its Relation to Parkinson’s Disease: A Review , 2022, Frontiers in Aging Neuroscience.
[45] M. Sommerauer,et al. Clinical and imaging evidence of brain-first and body-first Parkinson's disease , 2022, Neurobiology of Disease.
[46] Chih-Chiang Chan,et al. Mitochondrial Function and Parkinson’s Disease: From the Perspective of the Electron Transport Chain , 2021, Frontiers in Molecular Neuroscience.
[47] J. Trojanowski,et al. Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro , 2021, Acta neuropathologica communications.
[48] Chun-Pai Yang,et al. The Association of Olfactory Dysfunction With Depression, Cognition, and Disease Severity in Parkinson's Disease , 2021, Frontiers in Neurology.
[49] K. Satoh,et al. Tyrosine 136 phosphorylation of α-synuclein aggregates in the Lewy body dementia brain: involvement of serine 129 phosphorylation by casein kinase 2 , 2021, Acta Neuropathologica Communications.
[50] S. Shukla,et al. Non-motor symptoms in Parkinson's disease: Opening new avenues in treatment , 2021 .
[51] M. Muqit,et al. PTEN-induced kinase 1 (PINK1) and Parkin: Unlocking a mitochondrial quality control pathway linked to Parkinson's disease , 2021, Current Opinion in Neurobiology.
[52] R. Rajasekaran,et al. Alpha-Synuclein Aggregation in Parkinson's Disease , 2021, Frontiers in Medicine.
[53] D. Choi,et al. Targeting α‐synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease , 2021, British journal of pharmacology.
[54] M. Chartier-Harlin,et al. Alpha-Synuclein and Lipids: The Elephant in the Room? , 2021, Cells.
[55] R. Matthiesen,et al. Glycation modulates glutamatergic signaling and exacerbates Parkinson’s disease-like phenotypes , 2021, npj Parkinson's Disease.
[56] S. Pieraccini,et al. α-Synuclein: An All-Inclusive Trip Around its Structure, Influencing Factors and Applied Techniques , 2021, Frontiers in Chemistry.
[57] D. Aarsland,et al. Parkinson disease-associated cognitive impairment , 2021, Nature Reviews Disease Primers.
[58] Jacob O Day,et al. The Genetics of Parkinson’s Disease and Implications for Clinical Practice , 2021, Genes.
[59] H. Choi,et al. Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson’s disease: clues to early diagnosis and effective treatment , 2021, Archives of Pharmacal Research.
[60] K. Chaudhuri,et al. Gastrointestinal dysfunction in Parkinson’s disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation , 2021, Journal of Neurology.
[61] K. Bötzel,et al. Pathophysiological Changes in the Enteric Nervous System of Rotenone-Exposed Mice as Early Radiological Markers for Parkinson's Disease , 2021, Frontiers in Neurology.
[62] T. Dawson,et al. The cell biology of Parkinson’s disease , 2021, The Journal of cell biology.
[63] I. Charles,et al. Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation , 2021, NPJ Parkinson's disease.
[64] D. Brooks,et al. Preserved noradrenergic function in Parkinson's disease patients with rest tremor , 2021, Neurobiology of Disease.
[65] Safeera Khan,et al. Spectrum of Non-Motor Symptoms in Parkinson's Disease , 2021, Cureus.
[66] V. R. Muddapu,et al. Influence of energy deficiency on the subcellular processes of Substantia Nigra Pars Compacta cell for understanding Parkinsonian neurodegeneration , 2021, Scientific Reports.
[67] Dan Li,et al. Hierarchical chemical determination of amyloid polymorphs in neurodegenerative disease , 2021, Nature Chemical Biology.
[68] G. Miller,et al. Restoration of Noradrenergic Function in Parkinson’s Disease Model Mice , 2021, ASN neuro.
[69] B. Tang,et al. Olfactory Dysfunction Predicts Disease Progression in Parkinson’s Disease: A Longitudinal Study , 2020, Frontiers in Neuroscience.
[70] M. Kowalska,et al. Oxidative stress factors in Parkinson’s disease , 2020, Neural regeneration research.
[71] E. Khedr,et al. Depression and anxiety among patients with Parkinson’s disease: frequency, risk factors, and impact on quality of life , 2020, The Egyptian Journal of Neurology, Psychiatry and Neurosurgery.
[72] O. Rötzschke,et al. New Insights into Immune-Mediated Mechanisms in Parkinson’s Disease , 2020, International journal of molecular sciences.
[73] Fushun Wang,et al. Molecular Mechanisms of Glutamate Toxicity in Parkinson’s Disease , 2020, Frontiers in Neuroscience.
[74] M. Martínez-Vicente,et al. The Emerging Role of the Lysosome in Parkinson’s Disease , 2020, Cells.
[75] N. Maiti,et al. Structure Specific Neuro-toxicity of α-Synuclein Oligomer , 2020, bioRxiv.
[76] Orly Halperin,et al. Overconfidence in visual perception in Parkinson’s disease , 2020, bioRxiv.
[77] M. Tremblay,et al. Glutamate-induced excitotoxicity in Parkinson's disease: The role of glial cells. , 2020, Journal of pharmacological sciences.
[78] Kuo-Hsuan Chang,et al. The Role of Oxidative Stress in Parkinson’s Disease , 2020, Antioxidants.
[79] J. Jankovic,et al. Parkinson’s disease: etiopathogenesis and treatment , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[80] P. Yu,et al. Correction: S-Nitrosylation of G protein-coupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alpha-synuclein phosphorylation in an animal model of Parkinson’s disease , 2020, PloS one.
[81] Suneil K. Kalia,et al. LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease? , 2020, Frontiers in Neuroscience.
[82] J. Jankovic,et al. Parkinson disease and the immune system — associations, mechanisms and therapeutics , 2020, Nature Reviews Neurology.
[83] P. De Deurwaerdère,et al. The Noradrenergic System in Parkinson’s Disease , 2020, Frontiers in Pharmacology.
[84] Sarika Singh. Noradrenergic pathways of locus coeruleus in Parkinson’s and Alzheimer’s pathology , 2020, The International journal of neuroscience.
[85] Suneil K. Kalia,et al. Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein , 2020, Acta Neuropathologica Communications.
[86] L. Hool,et al. L-type Ca2+ channel–mediated Ca2+ influx adjusts neuronal mitochondrial function to physiological and pathophysiological conditions , 2020, Science Signaling.
[87] P. Agarwal,et al. Depression and Anxiety in Parkinson Disease. , 2020, Clinics in geriatric medicine.
[88] P. Heckman,et al. The contribution of Parkin, PINK1 and DJ‐1 genes to selective neuronal degeneration in Parkinson's disease , 2020, The European journal of neuroscience.
[89] A. Singleton,et al. Genetics of Parkinson's disease: An introspection of its journey towards precision medicine , 2020, Neurobiology of Disease.
[90] Dan Li,et al. Structural diversity of amyloid fibrils and advances in their structure determination. , 2020, Biochemistry.
[91] P. McLean,et al. Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway , 2020, Molecular Neurodegeneration.
[92] A. Albanese,et al. VPS35-Based Approach: A Potential Innovative Treatment in Parkinson's Disease , 2019, Front. Neurol..
[93] Seong-Tshool Hong,et al. Neuroprotective function of Omi to α-synuclein-induced neurotoxicity , 2019, Neurobiology of Disease.
[94] R. Wade-Martins,et al. Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease , 2019, Front. Mol. Neurosci..
[95] Susan S. Taylor,et al. The In Situ Structure of Parkinson’s Disease-Linked LRRK2 , 2019, Cell.
[96] Deming Zhao,et al. The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease , 2019, Front. Neurol..
[97] H. Berendse,et al. Hyposmia as a marker of (non-)motor disease severity in Parkinson’s disease , 2019, Journal of Neural Transmission.
[98] K. Yung,et al. Roles of Glutamate Receptors in Parkinson’s Disease , 2019, International journal of molecular sciences.
[99] S. Chandra,et al. Role of the endolysosomal system in Parkinson’s disease , 2019, Journal of neurochemistry.
[100] E. Sidransky,et al. Glucocerebrosidase and its relevance to Parkinson disease , 2019, Molecular Neurodegeneration.
[101] Nikhil Panicker,et al. Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease , 2019, Neuron.
[102] L. Bubacco,et al. Impaired dopamine metabolism in Parkinson’s disease pathogenesis , 2019, Molecular Neurodegeneration.
[103] S. Ho,et al. The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease , 2019, Translational Neurodegeneration.
[104] M. T. Pellecchia,et al. Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study , 2019, The Lancet Neurology.
[105] D. Fairlie,et al. Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles , 2019, Molecular Neurodegeneration.
[106] Michael D Healy,et al. Towards a molecular understanding of endosomal trafficking by Retromer and Retriever , 2019, Traffic.
[107] D. Eidelberg,et al. Serotonergic pathology and Braak's staging hypothesis in Parkinson's disease , 2019, The Lancet Neurology.
[108] Matthew J. Summers. Ubiquitin Proteasome System - Current Insights into Mechanism Cellular Regulation and Disease , 2019 .
[109] A. Xie,et al. Prion-Like Mechanisms in Parkinson’s Disease , 2019, Front. Neurosci..
[110] T. Graham,et al. Mammalian retromer is an adaptable scaffold for cargo sorting from endosomes , 2019, bioRxiv.
[111] J. Koistinaho,et al. Dysfunction of Cellular Proteostasis in Parkinson’s Disease , 2019, Front. Neurosci..
[112] V. Zinchenko,et al. Role of DJ-1 in the mechanism of pathogenesis of Parkinson's disease , 2019, Journal of Bioenergetics and Biomembranes.
[113] Jia-Da Li,et al. The Roles of Post-translational Modifications on α-Synuclein in the Pathogenesis of Parkinson’s Diseases , 2019, Front. Neurosci..
[114] W. Teo,et al. Parkinson's Disease and the Environment , 2019, Front. Neurol..
[115] Alexandra B. Nelson,et al. Circuit Mechanisms of Parkinson’s Disease , 2019, Neuron.
[116] Hui Zhang,et al. LRRK2 and mitochondria: Recent advances and current views , 2019, Brain Research.
[117] J. Greenland,et al. Parkinson’s Disease: Pathogenesis and Clinical Aspects , 2018 .
[118] L. Brodin,et al. Retromer in Synaptic Function and Pathology , 2018, Front. Synaptic Neurosci..
[119] H. Ni,et al. The Role of LRRK2 in Neurodegeneration of Parkinson Disease , 2018, Current neuropharmacology.
[120] J. Błaszczyk. The Emerging Role of Energy Metabolism and Neuroprotective Strategies in Parkinson's Disease , 2018, Front. Aging Neurosci..
[121] H. Düssmann,et al. ER stress signaling has an activating transcription factor 6α (ATF6)-dependent “off-switch” , 2018, The Journal of Biological Chemistry.
[122] Wei He,et al. Tau Pathology in Parkinson's Disease , 2018, Front. Neurol..
[123] M. Tansey,et al. α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson’s Disease Pathogenesis , 2018, Front. Neurosci..
[124] E. Mariman,et al. Differential protein expression of hippocampal cells associated with heavy metals (Pb, As, and MeHg) neurotoxicity: Deepening into the molecular mechanism of neurodegenerative diseases. , 2018, Journal of proteomics.
[125] R. Teasdale,et al. Structure of the membrane-assembled retromer coat determined by cryo-electron tomography , 2018, Nature.
[126] M. Rao,et al. Enteric nervous system manifestations of neurodegenerative disease , 2018, Brain Research.
[127] H. Mortiboys,et al. Mitochondrial abnormalities in Parkinson's disease and Alzheimer's disease: can mitochondria be targeted therapeutically? , 2018, Biochemical Society transactions.
[128] Hossein Sanjari Moghaddam,et al. Cerebrospinal Fluid C-Reactive Protein in Parkinson’s Disease: Associations with Motor and Non-motor Symptoms , 2018, NeuroMolecular Medicine.
[129] D. Krainc,et al. Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease , 2018, Cell and Tissue Research.
[130] C. Duyckaerts,et al. Is Lewy pathology in the human nervous system chiefly an indicator of neuronal protection or of toxicity? , 2018, Cell and Tissue Research.
[131] Joseph R. Patterson,et al. Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology , 2018, Neurobiology of Disease.
[132] R. Moratalla,et al. Cholesterol and multilamellar bodies: Lysosomal dysfunction in GBA-Parkinson disease , 2018, Autophagy.
[133] K. Jellinger,et al. Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease? , 2018, BMC Medicine.
[134] T. Südhof,et al. Cell Biology and Pathophysiology of α-Synuclein. , 2018, Cold Spring Harbor perspectives in medicine.
[135] Romain F. Laine,et al. C-terminal calcium binding of α-synuclein modulates synaptic vesicle interaction , 2018, Nature Communications.
[136] M. Sakharkar,et al. Naringenin Decreases α-Synuclein Expression and Neuroinflammation in MPTP-Induced Parkinson’s Disease Model in Mice , 2018, Neurotoxicity Research.
[137] Shi-feng Chu,et al. RTP801 is a critical factor in the neurodegeneration process of A53T α‐synuclein in a mouse model of Parkinson's disease under chronic restraint stress , 2018, British journal of pharmacology.
[138] D. Standaert,et al. Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease , 2018, Experimental Neurology.
[139] M. Mattson,et al. Intercellular transfer of pathogenic α-synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal , 2018, Neurobiology of Aging.
[140] L. Sanders,et al. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease , 2018, Neurobiology of Disease.
[141] A. Pandey,et al. GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers , 2018, Proceedings of the National Academy of Sciences.
[142] G. Novelli,et al. Genetics and Treatment Response in Parkinson’s Disease: An Update on Pharmacogenetic Studies , 2018, NeuroMolecular Medicine.
[143] David S. Park,et al. Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases , 2017, Cell Death & Differentiation.
[144] T. Amstislavskaya,et al. Suppression of autophagy in the brain of transgenic mice with overexpression of А53Т-mutant α-synuclein as an early event at synucleinopathy progression , 2017, Neuroscience Letters.
[145] L. Bubacco,et al. Recent findings on the physiological function of DJ-1: Beyond Parkinson's disease , 2017, Neurobiology of Disease.
[146] T. Gasser,et al. LRRK2 functions as a scaffolding kinase of ASK1-mediated neuronal cell death. , 2017, Biochimica et biophysica acta. Molecular cell research.
[147] O. El‐Agnaf,et al. Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice , 2017, Scientific Reports.
[148] J. V. Van Raamsdonk,et al. Activation of the mitochondrial unfolded protein response promotes longevity and dopamine neuron survival in Parkinson’s disease models , 2017, Scientific Reports.
[149] P. Hof,et al. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons , 2017, The Journal of Neuroscience.
[150] Alex R. Wade,et al. Abnormal visual gain control and excitotoxicity in early-onset Parkinson’s disease Drosophila models , 2017, Journal of neurophysiology.
[151] K. Caldwell,et al. Dysregulation of the Mitochondrial Unfolded Protein Response Induces Non-Apoptotic Dopaminergic Neurodegeneration in C. elegans Models of Parkinson's Disease , 2017, The Journal of Neuroscience.
[152] E. H. Howlett,et al. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease , 2017, Human molecular genetics.
[153] Andrew R. Bassett,et al. Alpha-synuclein induces the unfolded protein response in Parkinson’s disease SNCA triplication iPSC-derived neurons , 2017, Human molecular genetics.
[154] Matthias Mann,et al. Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis , 2017, eLife.
[155] David S. Park,et al. PINK1-mediated phosphorylation of LETM1 regulates mitochondrial calcium transport and protects neurons against mitochondrial stress , 2017, Nature Communications.
[156] S. Signorelli,et al. Metals and neurodegenerative diseases. A systematic review , 2017, Environmental research.
[157] S. Schneider,et al. Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature , 2017, Movement disorders : official journal of the Movement Disorder Society.
[158] Ori J. Lieberman,et al. α-Synuclein-Dependent Calcium Entry Underlies Differential Sensitivity of Cultured SN and VTA Dopaminergic Neurons to a Parkinsonian Neurotoxin , 2017, eNeuro.
[159] Wenzhang Wang,et al. Parkinson's disease-associated pathogenic VPS35 mutation causes complex I deficits. , 2017, Biochimica et biophysica acta. Molecular basis of disease.
[160] Songhee Jeon,et al. MPTP-induced vulnerability of dopamine neurons in A53T α-synuclein overexpressed mice with the potential involvement of DJ-1 downregulation , 2017, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology.
[161] D. Murry,et al. Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde. , 2017, Biochemical and biophysical research communications.
[162] P. Brundin,et al. Prying into the Prion Hypothesis for Parkinson's Disease , 2017, The Journal of Neuroscience.
[163] Yung-Yee Chang,et al. Identification of VPS35 p.D620N mutation-related Parkinson’s disease in a Taiwanese family with successful bilateral subthalamic nucleus deep brain stimulation: a case report and literature review , 2017, BMC Neurology.
[164] S. Chandra,et al. Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease , 2017, The Journal of Neuroscience.
[165] M. Romero-Ramos,et al. Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration , 2017, Neurobiology of Disease.
[166] H. Broxmeyer,et al. Parkinson disease–associated LRRK2 G2019S transgene disrupts marrow myelopoiesis and peripheral Th17 response , 2017, Journal of leukocyte biology.
[167] S. Zanata,et al. ER Stress Induced by Tunicamycin Triggers α-Synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinson’s Disease , 2017, Molecular Neurobiology.
[168] Jun Liu,et al. DJ-1 Inhibits α-Synuclein Aggregation by Regulating Chaperone-Mediated Autophagy , 2017, Front. Aging Neurosci..
[169] Jochen H Weishaupt,et al. Proteasome impairment by α-synuclein , 2017, PloS one.
[170] Sohee Jeon,et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease , 2017, Science.
[171] D. V. van Aalten,et al. Structure of PINK1 and mechanisms of Parkinson's disease-associated mutations , 2017, eLife.
[172] K. Ye,et al. TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson’s disease , 2017, Proceedings of the National Academy of Sciences.
[173] R. Kalb,et al. Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration , 2017, Nature Neuroscience.
[174] W. Banks,et al. Transmission of α-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson’s disease? , 2017, Acta Neuropathologica Communications.
[175] A. Schapira,et al. The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice , 2017, Brain : a journal of neurology.
[176] M. Cookson,et al. Alpha‐synuclein triggers T‐cell response. Is Parkinson's disease an autoimmune disorder? , 2017, Movement disorders : official journal of the Movement Disorder Society.
[177] P. Su,et al. A peptide disrupting the D2R-DAT interaction protects against dopamine neurotoxicity , 2017, Experimental Neurology.
[178] K. Lim,et al. Reactive oxygen species trigger Parkin/PINK1 pathway–dependent mitophagy by inducing mitochondrial recruitment of Parkin , 2017, The Journal of Biological Chemistry.
[179] P. Calabresi,et al. Cerebrospinal fluid β‐glucocerebrosidase activity is reduced in parkinson's disease patients , 2017, Movement disorders : official journal of the Movement Disorder Society.
[180] J. Kulisevsky,et al. N370S‐GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease , 2017, Movement disorders : official journal of the Movement Disorder Society.
[181] D. Meierhofer,et al. Progression of pathology in PINK1-deficient mouse brain from splicing via ubiquitination, ER stress, and mitophagy changes to neuroinflammation , 2017, Journal of Neuroinflammation.
[182] H. Erdjument-Bromage,et al. The Ubiquitination of PINK1 Is Restricted to Its Mature 52-kDa Form , 2017, Cell reports.
[183] R. Martino,et al. Onset and progression factors in Parkinson's disease: A systematic review , 2017, Neurotoxicology.
[184] Thomas Theelen,et al. Ocular and visual disorders in Parkinson's disease: Common but frequently overlooked. , 2017, Parkinsonism & related disorders.
[185] Min Zhu,et al. DJ-1, a Parkinson's disease related protein, aggregates under denaturing conditions and co-aggregates with α-synuclein through hydrophobic interaction. , 2017, Biochimica et biophysica acta. General subjects.
[186] E. Masliah,et al. Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson’s disease , 2017, Scientific Reports.
[187] S. Koyama,et al. Mechanisms underlying extensive Ser129-phosphorylation in α-synuclein aggregates , 2017, Acta neuropathologica communications.
[188] K. Chaudhuri,et al. Non-motor features of Parkinson disease , 2017, Nature Reviews Neuroscience.
[189] C. Crosio,et al. Role of LRRK2 in the regulation of dopamine receptor trafficking , 2017, PloS one.
[190] T. Asil,et al. Motor and Non-Motor Symptoms in Parkinson's Disease: Effects on Quality of Life. , 2017, Noro psikiyatri arsivi.
[191] S. Zaichick,et al. The role of Ca2+ signaling in Parkinson's disease , 2017, Disease Models & Mechanisms.
[192] Z. Wszolek,et al. The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity , 2017, Molecular Neurodegeneration.
[193] M. Muqit,et al. PINK1 and Parkin: emerging themes in mitochondrial homeostasis. , 2017, Current opinion in cell biology.
[194] N. Bouslam,et al. LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson's Disease , 2017, Parkinson's disease.
[195] J. Segura-Aguilar,et al. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease? , 2017, ACS chemical neuroscience.
[196] W. Meissner,et al. Epidemiology, environmental risk factors and genetics of Parkinson's disease. , 2017, Presse medicale.
[197] J. Massano,et al. An updated review of Parkinson's disease genetics and clinicopathological correlations , 2017, Acta neurologica Scandinavica.
[198] I. Toni,et al. Dopamine controls Parkinson’s tremor by inhibiting the cerebellar thalamus , 2017, Brain : a journal of neurology.
[199] Matthieu Drouyer,et al. LRRK2 detection in human biofluids: potential use as a Parkinson's disease biomarker? , 2017, Biochemical Society transactions.
[200] T. Dawson,et al. PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival. , 2017, Cell reports.
[201] She Chen,et al. PINK1-dependent phosphorylation of PINK1 and Parkin is essential for mitochondrial quality control , 2016, Cell Death & Disease.
[202] J. Bonifacino,et al. Structural Mechanism for Cargo Recognition by the Retromer Complex , 2016, Cell.
[203] P. Wang,et al. Blood Plasma of Patients with Parkinson's Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity , 2016, Parkinson's disease.
[204] M. Farrer,et al. Heterozygous PINK1 p.G411S increases risk of Parkinson’s disease via a dominant-negative mechanism , 2016, Brain : a journal of neurology.
[205] K. Chung,et al. Leucine-rich repeat kinase 2 exacerbates neuronal cytotoxicity through phosphorylation of histone deacetylase 3 and histone deacetylation , 2016, Human molecular genetics.
[206] T. Monks,et al. From the Cover: Arsenic Induces Accumulation of α-Synuclein: Implications for Synucleinopathies and Neurodegeneration. , 2016, Toxicological sciences : an official journal of the Society of Toxicology.
[207] Kwang-Soo Kim,et al. LRRK2 interferes with aggresome formation for autophagic clearance , 2016, Molecular and Cellular Neuroscience.
[208] J. Troncoso,et al. Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration. , 2016, The Journal of clinical investigation.
[209] D. Krainc,et al. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons , 2016, The Journal of Neuroscience.
[210] H. McBride,et al. Parkinson’s Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation , 2016, Cell.
[211] Andrew B West,et al. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons , 2016, The Journal of Neuroscience.
[212] R. Teasdale,et al. Parkinson Disease-linked Vps35 R524W Mutation Impairs the Endosomal Association of Retromer and Induces α-Synuclein Aggregation* , 2016, The Journal of Biological Chemistry.
[213] N. Wood,et al. Mitofusin-mediated ER stress triggers neurodegeneration in pink1/parkin models of Parkinson's disease , 2016, Cell Death and Disease.
[214] I. Alonso,et al. DJ-1 linked parkinsonism (PARK7) is associated with Lewy body pathology. , 2016, Brain : a journal of neurology.
[215] Mandar S Jog,et al. An update on the diagnosis and treatment of Parkinson disease , 2016, Canadian Medical Association Journal.
[216] N. Quan,et al. Neuroinflammation: the devil is in the details , 2016, Journal of neurochemistry.
[217] Yuanjun Guo,et al. Long Non-coding RNA HOTAIR Promotes Parkinson's Disease Induced by MPTP Through up-regulating the Expression of LRRK2. , 2016, Current neurovascular research.
[218] Charles D. Schwieters,et al. Solid-State NMR Structure of a Pathogenic Fibril of Full-Length Human α-Synuclein , 2016, Nature Structural &Molecular Biology.
[219] E. Balafas,et al. GABA transmission via ATP-dependent K+ channels regulates α-synuclein secretion in mouse striatum. , 2016, Brain : a journal of neurology.
[220] C. Ross,et al. Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models. , 2016, Human molecular genetics.
[221] J. Winkler,et al. Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α-synuclein transgenic rat model of Parkinson's disease , 2016, Neurobiology of Disease.
[222] D. Turnbull,et al. Mitochondrial DNA Depletion in Respiratory Chain–Deficient Parkinson Disease Neurons , 2016, Annals of neurology.
[223] A. Schapira,et al. Endoplasmic reticulum and lysosomal Ca2+ stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts , 2016, Cell calcium.
[224] M. Murray,et al. Transmission of Soluble and Insoluble &agr;-Synuclein to Mice , 2015, Journal of neuropathology and experimental neurology.
[225] D. Hausenloy,et al. Parkinson's disease proteins: Novel mitochondrial targets for cardioprotection , 2015, Pharmacology & therapeutics.
[226] P. Chinnery,et al. Mitochondrial dysfunction in aging: Much progress but many unresolved questions , 2015, Biochimica et biophysica acta.
[227] G. Kim,et al. The Role of Oxidative Stress in Neurodegenerative Diseases , 2015, Experimental neurobiology.
[228] B. Pakkenberg,et al. Lack of Neuronal IFN-β-IFNAR Causes Lewy Body- and Parkinson’s Disease-like Dementia , 2015, Cell.
[229] Wenzhang Wang,et al. Parkinson’s disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes , 2015, Nature Medicine.
[230] P. Mastroberardino,et al. Metals and neurodegeneration , 2015, Neurobiology of Disease.
[231] Nicholas K. Sauter,et al. Structure of the toxic core of α-synuclein from invisible crystals , 2015, Nature.
[232] L. Mei,et al. VPS35 Deficiency or Mutation Causes Dopaminergic Neuronal Loss by Impairing Mitochondrial Fusion and Function. , 2015, Cell reports.
[233] S. Weber,et al. Exogenous α-synuclein induces toll-like receptor 4 dependent inflammatory responses in astrocytes , 2015, BMC Neuroscience.
[234] J. Burman,et al. The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy , 2015, Nature.
[235] W. Scheper,et al. The unfolded protein response in neurodegenerative diseases: a neuropathological perspective , 2015, Acta Neuropathologica.
[236] Victor Tapias,et al. shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. , 2015, The Journal of clinical investigation.
[237] S. Paek,et al. Mitochondrial Dysfunction in Parkinson's Disease , 2015, Experimental neurobiology.
[238] V. Rao,et al. Evaluation of PARKIN gene variants in West Bengal Parkinson’s disease patients , 2015, Journal of Human Genetics.
[239] A. Schapira. Glucocerebrosidase and Parkinson disease: Recent advances , 2015, Molecular and Cellular Neuroscience.
[240] C. Gerloff,et al. Visual Attention and Saccadic Oculomotor Control in Parkinson's Disease , 2015, European Neurology.
[241] B. Pająk,et al. Calcium Homeostasis and ER Stress in Control of Autophagy in Cancer Cells , 2015, BioMed research international.
[242] L. Aguayo,et al. Extracellular α‐synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane , 2015, Journal of neurochemistry.
[243] Seokjoong Kim,et al. Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation , 2015, Experimental & Molecular Medicine.
[244] Laura M. Vecchio,et al. Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits , 2015, Neurobiology of Disease.
[245] O. Isacson,et al. Progressive decline of glucocerebrosidase in aging and Parkinson's disease , 2015, Annals of Clinical and Translational Neurology.
[246] R. Youle,et al. The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease , 2015, Neuron.
[247] N. Alenina,et al. The role of serotonin in adult hippocampal neurogenesis , 2015, Behavioural Brain Research.
[248] A. Jeans,et al. Is Parkinson's Disease Truly a Prion-Like Disorder? An Appraisal of Current Evidence , 2015, Neurology research international.
[249] A. Wen,et al. Protective Effects of Lycium barbarum Polysaccharide on 6-OHDA-Induced Apoptosis in PC12 Cells through the ROS-NO Pathway , 2014, Molecules.
[250] G. Forloni,et al. The Parkinson's Disease-Related Protein DJ-1 Protects Dopaminergic Neurons in vivo and Cultured Cells from Alpha-Synuclein and 6-Hydroxydopamine Toxicity , 2014, Neurodegenerative Diseases.
[251] N. Jetté,et al. The prevalence of Parkinson's disease: A systematic review and meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.
[252] S. Frautschy,et al. Molecular Chaperone Dysfunction in Neurodegenerative Diseases and Effects of Curcumin , 2014, BioMed research international.
[253] Yi Zhao,et al. In vivo evidence of pathogenicity of VPS35 mutations in the Drosophila , 2014, Molecular Brain.
[254] G. Halliday,et al. Alpha-synuclein biology in Lewy body diseases , 2014, Alzheimer's Research & Therapy.
[255] J. Goodwin,et al. Interactions between Calcium and Alpha-Synuclein in Neurodegeneration , 2014, Biomolecules.
[256] E. Bézard,et al. Lysosomes and α-synuclein form a dangerous duet leading to neuronal cell death , 2014, Front. Neuroanat..
[257] S. Lindquist,et al. Calcineurin determines toxic versus beneficial responses to α-synuclein , 2014, Proceedings of the National Academy of Sciences.
[258] Chuong B. Do,et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.
[259] M. Repici,et al. DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease , 2014, Cell Death and Disease.
[260] D. Selkoe,et al. Soluble, Prefibrillar α-Synuclein Oligomers Promote Complex I-dependent, Ca2+-induced Mitochondrial Dysfunction* , 2014, The Journal of Biological Chemistry.
[261] Bidisha Roy,et al. Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease. , 2014, Human molecular genetics.
[262] Soojay Banerjee,et al. PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity , 2014, The Journal of cell biology.
[263] C. Hetz,et al. Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1 , 2014, Proceedings of the National Academy of Sciences.
[264] D. Sulzer,et al. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration , 2014, Nature Communications.
[265] Heung-Chin Cheng,et al. Prediction of the Repeat Domain Structures and Impact of Parkinsonism‐Associated Variations on Structure and Function of all Functional Domains of Leucine‐Rich Repeat Kinase 2 (LRRK2) , 2014, Human mutation.
[266] S. Tenreiro,et al. Protein phosphorylation in neurodegeneration: friend or foe? , 2014, Front. Mol. Neurosci..
[267] A. Velázquez‐Campoy,et al. Structural and Functional Analysis of Novel Human Cytochrome c Targets in Apoptosis* , 2014, Molecular & Cellular Proteomics.
[268] G. Halliday,et al. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. , 2014, Brain : a journal of neurology.
[269] D. Turnbull,et al. Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?☆ , 2014, Ageing Research Reviews.
[270] A. Destée,et al. Involvement of the immune system, endocytosis and EIF2 signaling in both genetically determined and sporadic forms of Parkinson's disease , 2014, Neurobiology of Disease.
[271] C. Burd,et al. Retromer: a master conductor of endosome sorting. , 2014, Cold Spring Harbor perspectives in biology.
[272] S. Goldman. Environmental toxins and Parkinson's disease. , 2014, Annual review of pharmacology and toxicology.
[273] R. Motter,et al. In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain , 2014, Neuroscience.
[274] H. Mortiboys,et al. Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. , 2013, Brain : a journal of neurology.
[275] Xinglong Wang,et al. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. , 2013, Free radical biology & medicine.
[276] S. Fox. Non-dopaminergic Treatments for Motor Control in Parkinson’s Disease , 2013, Drugs.
[277] M. Chesselet,et al. Mitochondrial dysfunction and oxidative stress in Parkinson's disease , 2013, Progress in Neurobiology.
[278] D. Dexter,et al. Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins. , 2013, Brain : a journal of neurology.
[279] D. Standaert,et al. MHCII Is Required for α-Synuclein-Induced Activation of Microglia, CD4 T Cell Proliferation, and Dopaminergic Neurodegeneration , 2013, The Journal of Neuroscience.
[280] C. Klein,et al. The many faces of alpha‐synuclein mutations , 2013, Movement disorders : official journal of the Movement Disorder Society.
[281] Gunnar Brunborg,et al. Metal Dyshomeostasis and Inflammation in Alzheimer's and Parkinson's Diseases: Possible Impact of Environmental Exposures , 2013, Oxidative medicine and cellular longevity.
[282] E. Masliah,et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia , 2013, Nature Communications.
[283] M. Duchen,et al. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage , 2013, Neurochemistry International.
[284] Heung-Chin Cheng,et al. Analysis of LRRK2 accessory repeat domains: prediction of repeat length, number and sites of Parkinson's disease mutations. , 2012, Biochemical Society transactions.
[285] J. Hardy,et al. Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains , 2012, Annals of neurology.
[286] M. Cookson. Parkinsonism due to mutations in PINK1, parkin, and DJ-1 and oxidative stress and mitochondrial pathways. , 2012, Cold Spring Harbor perspectives in medicine.
[287] A. Winslow,et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers , 2012, Molecular Neurodegeneration.
[288] Xiaoguang Luo,et al. Association of Parkinson’s disease with six single nucleotide polymorphisms located in four PARK genes in the northern Han Chinese population , 2012, Journal of Clinical Neuroscience.
[289] T. Outeiro,et al. Alpha-synuclein: from secretion to dysfunction and death , 2012, Cell Death and Disease.
[290] N. Muzyczka,et al. Glucose regulated protein 78 diminishes α-synuclein neurotoxicity in a rat model of Parkinson disease. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[291] J. Im,et al. DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway. , 2012, Human molecular genetics.
[292] S. Nataf,et al. ER stress inhibits neuronal death by promoting autophagy , 2012, Autophagy.
[293] M. Duchen,et al. Dopamine Induced Neurodegeneration in a PINK1 Model of Parkinson's Disease , 2012, PloS one.
[294] A. Schapira,et al. A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[295] L. Birnbaumer,et al. Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling. , 2012, The Journal of clinical investigation.
[296] J. Troncoso,et al. Endoplasmic Reticulum Stress Is Important for the Manifestations of α-Synucleinopathy In Vivo , 2012, The Journal of Neuroscience.
[297] M. Rohde,et al. Throughput optimized a-Si/μc-Si tandem solar cells on sputter-etched ZnO substrates , 2012 .
[298] F. Sterky,et al. Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons. , 2012, Human molecular genetics.
[299] Xiongwei Zhu,et al. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. , 2012, Human molecular genetics.
[300] J. Cannon,et al. The role of environmental exposures in neurodegeneration and neurodegenerative diseases. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.
[301] P. Walter,et al. The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation , 2011, Science.
[302] J. Sanders,et al. Leucine-Rich Repeat Kinase 2 (LRRK2) Cellular Biology: A Review of Recent Advances in Identifying Physiological Substrates and Cellular Functions , 2011, Journal of neurogenetics.
[303] S. Koyama,et al. Authentically Phosphorylated α-Synuclein at Ser129 Accelerates Neurodegeneration in a Rat Model of Familial Parkinson's Disease , 2011, The Journal of Neuroscience.
[304] U. Mosimann,et al. Visual symptoms in Parkinson's disease and Parkinson's disease dementia , 2011, Movement disorders : official journal of the Movement Disorder Society.
[305] I. Martin,et al. Recent advances in the genetics of Parkinson's disease. , 2011, Annual review of genomics and human genetics.
[306] F. Wang,et al. GDNF-pretreatment enhances the survival of neural stem cells following transplantation in a rat model of Parkinson's disease , 2011, Neuroscience Research.
[307] D. Rubinsztein,et al. The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity , 2011, Cell Death and Disease.
[308] H. Adami,et al. Epidemiology and etiology of Parkinson’s disease: a review of the evidence , 2011, European Journal of Epidemiology.
[309] E. Masliah,et al. Hyperphosphorylated Tau in an α‐synuclein‐overexpressing transgenic model of Parkinson’s disease , 2011, The European journal of neuroscience.
[310] J. Zeng,et al. LRRK2 R1398H polymorphism is associated with decreased risk of Parkinson's disease in a Han Chinese population. , 2011, Parkinsonism & related disorders.
[311] D. Howells,et al. Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson’s disease , 2011, Acta Neuropathologica.
[312] H. Zhou,et al. Confirmation of LRRK2 S1647T variant as a risk factor for Parkinson’s disease in Southern China , 2011, European journal of neurology.
[313] B. Meier,et al. Motor sequence learning performance in Parkinson’s disease patients depends on the stage of disease , 2011, Brain and Cognition.
[314] Miguel Ángel Martínez,et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.
[315] Fred H. Gage,et al. In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.
[316] J. Pu,et al. A study of six point mutation analysis of LRRK2 gene in Chinese mainland patients with Parkinson’s disease , 2011, Neurological Sciences.
[317] W. Burke,et al. The Neurotoxicity of DOPAL: Behavioral and Stereological Evidence for Its Role in Parkinson Disease Pathogenesis , 2010, PloS one.
[318] Mark R. Cookson,et al. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease , 2010, Nature Reviews Neuroscience.
[319] C. Tanner,et al. Familial aggregation of Parkinson's disease in a multiethnic community‐based case‐control study , 2010, Movement disorders : official journal of the Movement Disorder Society.
[320] B. Giasson,et al. L10p and P158DEL DJ‐1 mutations cause protein instability, aggregation, and dimerization impairments , 2010, Journal of neuroscience research.
[321] I. Mata,et al. The Genetics of Parkinson Disease , 2010, Journal of geriatric psychiatry and neurology.
[322] B. Zhivotovsky,et al. Mitochondrial regulation of cell death: processing of apoptosis-inducing factor (AIF). , 2010, Biochemical and biophysical research communications.
[323] C. Sampaio,et al. Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. , 2010, Parkinsonism & related disorders.
[324] R. de Silva,et al. LRRK2 G2019S in the North African Population: A Review , 2010, European Neurology.
[325] Hee-Jin Kim,et al. The LRRK2 G2385R variant is a risk factor for sporadic Parkinson's disease in the Korean population. , 2010, Parkinsonism & related disorders.
[326] R. Raghubir,et al. Endoplasmic Reticulum Stress Plays Critical Role in Brain Damage After Cerebral Ischemia/Reperfusion in Rats , 2010, Neurotoxicity Research.
[327] Bradley A. Evanoff,et al. Geographic and Ethnic Variation in Parkinson Disease: A Population-Based Study of US Medicare Beneficiaries , 2010, Neuroepidemiology.
[328] Atsushi Tanaka,et al. PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin , 2010, PLoS biology.
[329] M. Nalls,et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. , 2009, The New England journal of medicine.
[330] Nir Giladi,et al. The LRRK2 G2019S mutation as the cause of Parkinson’s disease in Ashkenazi Jews , 2009, Journal of Neural Transmission.
[331] T. Niki,et al. Oxidative Status of DJ-1-dependent Activation of Dopamine Synthesis through Interaction of Tyrosine Hydroxylase and 4-Dihydroxy-l-phenylalanine (l-DOPA) Decarboxylase with DJ-1* , 2009, The Journal of Biological Chemistry.
[332] R. Youle,et al. Parkin-induced mitophagy in the pathogenesis of Parkinson disease , 2009, Autophagy.
[333] A. H. Tsang,et al. Oxidative and nitrosative stress in Parkinson's disease. , 2009, Biochimica et biophysica acta.
[334] Wolfgang Wurst,et al. Loss of Parkin or PINK1 Function Increases Drp1-dependent Mitochondrial Fragmentation* , 2009, The Journal of Biological Chemistry.
[335] Ole Isacson,et al. Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy , 2009, The Journal of Neuroscience.
[336] S. Kerk,et al. Dopamine auto‐oxidation aggravates non‐apoptotic cell death induced by over‐expression of human A53T mutant alpha‐synuclein in dopaminergic PC12 cells , 2009, Journal of neurochemistry.
[337] M. Cookson,et al. Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions , 2009, ASN neuro.
[338] M. Goldenberg. Medical management of Parkinson's disease. , 2008, P & T : a peer-reviewed journal for formulary management.
[339] C. Singer,et al. Is the G2019S LRRK2 mutation common in all southern European populations? , 2008, Journal of Clinical Neuroscience.
[340] A. Stępień,et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism , 2008, Neuroscience Letters.
[341] M. Farrer,et al. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease , 2008, Annals of neurology.
[342] M. Farrer,et al. Genomic investigation of α‐synuclein multiplication and parkinsonism , 2008, Annals of neurology.
[343] C. Davie. A review of Parkinson's disease. , 2008, British medical bulletin.
[344] N. Quinn,et al. Antineuronal antibodies in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.
[345] D. Eliezer,et al. Structural effects of Parkinson's disease linked DJ‐1 mutations , 2008, Protein science : a publication of the Protein Society.
[346] Daniela Berg,et al. Biomarkers for the Early Detection of Parkinson’s and Alzheimer’s Disease , 2008, Neurodegenerative Diseases.
[347] M. Parihar,et al. Mitochondrial association of alpha-synuclein causes oxidative stress , 2008, Cellular and Molecular Life Sciences.
[348] B. Cagniard,et al. Unregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice , 2008, The Journal of Neuroscience.
[349] Vladimir N. Uversky,et al. Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation , 2007 .
[350] P. Calabresi,et al. Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[351] P. Walter,et al. Signal integration in the endoplasmic reticulum unfolded protein response , 2007, Nature Reviews Molecular Cell Biology.
[352] Sarika Singh,et al. Apoptotic neuronal death in Parkinson's disease: Involvement of nitric oxide , 2007, Brain Research Reviews.
[353] J. Gorell,et al. Whole-Body Lifetime Occupational Lead Exposure and Risk of Parkinson’s Disease , 2006, Environmental health perspectives.
[354] David Oakes,et al. Head injury and Parkinson's disease risk in twins , 2006, Annals of neurology.
[355] K. Xia,et al. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. , 2006, Human molecular genetics.
[356] B. Jeon,et al. Protective role of heat shock and heat shock protein 70 in lactacystin-induced cell death both in the rat substantia nigra and PC12 cells , 2006, Brain Research.
[357] B. Zhivotovsky,et al. Multiple pathways of cytochrome c release from mitochondria in apoptosis. , 2006, Biochimica et biophysica acta.
[358] Andrew B West,et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[359] B. Sonawane,et al. Neurodegenerative Diseases: An Overview of Environmental Risk Factors , 2005, Environmental health perspectives.
[360] Thomas Meitinger,et al. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.
[361] A. Ludolph,et al. Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration , 2004, Journal of Neural Transmission.
[362] S. Leonard,et al. Cadmium inhibits the electron transfer chain and induces reactive oxygen species. , 2004, Free radical biology & medicine.
[363] J. Troncoso,et al. S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function , 2004, Science.
[364] R. Nussbaum,et al. Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.
[365] P. Vandenabeele,et al. Toxic proteins released from mitochondria in cell death , 2004, Oncogene.
[366] Andre Parent,et al. Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration , 2003, Annals of neurology.
[367] B. Oostra,et al. DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism , 2003, Neurological Sciences.
[368] W. Dauer,et al. Parkinson's Disease Mechanisms and Models , 2003, Neuron.
[369] Lorene M Nelson,et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. , 2003, American journal of epidemiology.
[370] G. Fiskum,et al. Mitochondrial Mechanisms of Neural Cell Death and Neuroprotective Interventions in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.
[371] Todd B. Sherer,et al. Selective microglial activation in the rat rotenone model of Parkinson's disease , 2003, Neuroscience Letters.
[372] G. Escames,et al. Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion , 2003, Neurobiology of Aging.
[373] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[374] Lloyd A Greene,et al. Endoplasmic Reticulum Stress and the Unfolded Protein Response in Cellular Models of Parkinson's Disease , 2002, The Journal of Neuroscience.
[375] Patrizia Rizzu,et al. Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.
[376] Patrik Brundin,et al. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. , 2002, Human molecular genetics.
[377] M. Beal,et al. Caspase-9 Activation Results in Downstream Caspase-8 Activation and Bid Cleavage in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson's Disease , 2001, The Journal of Neuroscience.
[378] Nikki J. Holbrook,et al. Oxidants, oxidative stress and the biology of ageing , 2000, Nature.
[379] M. Hengartner. The biochemistry of apoptosis , 2000, Nature.
[380] P. Krammer,et al. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. , 2000, Experimental cell research.
[381] E. Hirsch,et al. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[382] D. Nicholson,et al. Caspase structure, proteolytic substrates, and function during apoptotic cell death , 1999, Cell Death and Differentiation.
[383] J. Gorell,et al. Occupational Metal Exposures and the Risk of Parkinson’s Disease , 1999, Neuroepidemiology.
[384] C. Benoist,et al. Mice lacking all conventional MHC class II genes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[385] N. Thornberry. Caspases: key mediators of apoptosis. , 1998, Chemistry & biology.
[386] S. Minoshima,et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.
[387] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[388] K. Marder,et al. Risk of Parkinson's disease among first-degree relatives , 1996, Neurology.
[389] Peter Riederer,et al. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.
[390] S. Korsmeyer,et al. Role of BCL-2 in the survival and function of developing and mature sympathetic neurons , 1995, Neuron.
[391] Minoru Harada,et al. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.
[392] P. Mcgeer,et al. Microglial response to 6-hydroxydopamine-induced substantia nigra lesions , 1989, Brain Research.
[393] OUP accepted manuscript , 2022, Brain.
[394] D. Dickson. Neuropathology of Parkinson disease. , 2018, Parkinsonism & related disorders.
[395] M. Islam,et al. G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain , 2018, Human molecular genetics.
[396] W. Voos,et al. Mitochondrial quality control by the Pink1/Parkin system , 2016, Cell and Tissue Research.
[397] Christine Klein,et al. Genetics of Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.
[398] P. Heutink,et al. Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6 , 2010, Cell Death and Differentiation.
[399] P. Jenner. Oxidative stress and Parkinson's disease. , 2007, Handbook of clinical neurology.
[400] P. Kolatkar,et al. The LRRK2 Gly2385Arg variant is associated with Parkinson’s disease: genetic and functional evidence , 2006, Human Genetics.
[401] H. Lipp,et al. Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[402] H. Ichinose,et al. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain , 2000, Journal of Neural Transmission.
[403] E. Zamrini,et al. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. , 1997, The American journal of pathology.